cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation

Omecamtiv mecarbil (OM), a direct myosin motor activator, is currently being tested as a therapeutic replacement for conventional inotropes in heart failure (HF) patients. It is known that HF patients exhibit dysregulated β-adrenergic signaling and decreased cardiac myosin-binding protein C (cMyBPC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamidi, Ranganath, Holmes, Joshua B., Doh, Chang Yoon, Dominic, Katherine L., Madugula, Nikhil, Stelzer, Julian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953254/
https://www.ncbi.nlm.nih.gov/pubmed/33688929
http://dx.doi.org/10.1085/jgp.202012816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953254/
https://www.ncbi.nlm.nih.gov/pubmed/33688929
http://dx.doi.org/10.1085/jgp.202012816

Ejemplares similares